Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, retrospective, cross-sectional study for dysgeusia during chemotherapy for solid tumors

Next Previous
Trial Profile

An observational, retrospective, cross-sectional study for dysgeusia during chemotherapy for solid tumors

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Bicalutamide (Primary) ; Bleomycin (Primary) ; Bortezomib (Primary) ; Brentuximab vedotin (Primary) ; Capecitabine (Primary) ; Carboplatin (Primary) ; Carfilzomib (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dacarbazine (Primary) ; Denosumab (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Epirubicin (Primary) ; Etoposide (Primary) ; Exemestane (Primary) ; Filgrastim (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Fulvestrant (Primary) ; Gefitinib (Primary) ; Gemcitabine (Primary) ; Ifosfamide (Primary) ; Irinotecan (Primary) ; Leuprorelin (Primary) ; Methotrexate (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Rituximab (Primary) ; Temozolomide (Primary) ; Thalidomide (Primary) ; Topotecan (Primary) ; Trastuzumab (Primary) ; Vinblastine (Primary) ; Vincristine (Primary) ; Vinorelbine (Primary) ; Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Bone cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Early breast cancer; Gastric cancer; Head and neck cancer; Intestinal cancer; Liver cancer; Lung cancer; Malignant melanoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Penile cancer; Prostate cancer; Skin cancer; Soft tissue sarcoma; Solid tumours; Testicular cancer; Thyroid cancer; Urogenital cancer; Uterine cancer
  • Focus Adverse reactions

Most Recent Events

  • 04 Jan 2022 New trial record
  • 01 Jan 2022 Results published in the Supportive Care in Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top